Guardant Health, Inc. $GH Stock Bought by Ethic Inc.

Ethic Inc. raised its position in Guardant Health, Inc. (NASDAQ:GH) by 77.7% in the third quarter, Holdings Channel reports. The institutional investor owned 9,924 shares of the company’s stock after purchasing an additional 4,339 shares during the period. Ethic Inc.’s holdings in Guardant Health were worth $1,770,000 as of its most recent filing with the SEC.

Other large investors have also modified their holdings of the company. CenterBook Partners LP acquired a new stake in shares of Guardant Health during the 3rd quarter valued at about $585,000. Heritage Family Offices LLP acquired a new position in Guardant Health in the 3rd quarter worth about $82,000. Kestra Advisory Services LLC acquired a new position in Guardant Health in the 3rd quarter worth about $479,000. Mirae Asset Global Investments Co. Ltd. purchased a new position in Guardant Health during the third quarter worth approximately $1,345,000. Finally, ProShare Advisors LLC boosted its position in Guardant Health by 6.5% during the third quarter. ProShare Advisors LLC now owns 5,005 shares of the company’s stock worth $893,000 after purchasing an additional 304 shares in the last quarter. Institutional investors and hedge funds own 92.60% of the company’s stock.

Guardant Health Stock Up 0.1%

GH stock opened at $154.86 on Friday. Guardant Health, Inc. has a 52 week low of $74.55 and a 52 week high of $191.05. The firm has a 50-day simple moving average of $168.83 and a 200-day simple moving average of $132.81. The stock has a market capitalization of $20.95 billion, a P/E ratio of -42.08 and a beta of 1.67.

Guardant Health (NASDAQ:GH) last issued its quarterly earnings results on Thursday, November 5th. The company reported ($0.29) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.46. The company had revenue of $360.98 million during the quarter, compared to analysts’ expectations of $350.72 million. During the same period in the prior year, the business posted ($0.74) earnings per share. The company’s quarterly revenue was up 36.1% compared to the same quarter last year. On average, analysts expect that Guardant Health, Inc. will post -3.08 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages have commented on GH. Rothschild & Co Redburn started coverage on Guardant Health in a report on Tuesday, September 8th. They issued a “buy” rating and a $203.00 price objective on the stock. Barclays upped their target price on Guardant Health from $200.00 to $220.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 7th. UBS Group increased their target price on Guardant Health from $175.00 to $225.00 and gave the company a “buy” rating in a research report on Wednesday, September 9th. Morgan Stanley increased their target price on Guardant Health from $185.00 to $200.00 and gave the company an “overweight” rating in a research report on Monday, October 12th. Finally, Roth Capital initiated coverage on shares of Guardant Health in a research note on Thursday, October 22nd. They issued a “buy” rating and a $200.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $190.88.

Insider Transactions at Guardant Health

In other news, CTO Darya Chudova sold 7,738 shares of the firm’s stock in a transaction that occurred on Tuesday, September 15th. The stock was sold at an average price of $178.00, for a total value of $1,377,364.00. Following the transaction, the chief technology officer owned 70,635 shares in the company, valued at $12,573,030. This trade represents a 9.87% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Alex M. Azar II sold 826 shares of Guardant Health stock in a transaction that occurred on Wednesday, September 16th. The stock was sold at an average price of $175.00, for a total value of $144,550.00. Following the completion of the sale, the director directly owned 825 shares in the company, valued at $144,375. This represents a 50.03% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 53,155 shares of company stock valued at $9,107,025 in the last 90 days. Corporate insiders own 5.60% of the company’s stock.

Guardant Health Profile

Guardant Health is a precision oncology company that develops blood- and tissue-based tests to help guide cancer care. Founded in 2012 by Helmy Eltoukhy and AmirAli Talasaz, the company focuses on using genomic information to support cancer detection, treatment selection and disease monitoring. Its products include Guardant360 tests, which analyze tumor-related genetic changes to help inform treatment decisions, and Guardant Reveal, which is designed to detect residual or recurring cancer after treatment.